SphygmoCor XCEL PWA and PWV Non-invasive Medical D

The National Institute of Child Health and Human Development (NICHD), in support of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), intends to procure a SphygmoCor XCEL PWA and PWV Non-invasive Medical Device from ATCOR MEDICAL INC USA through a non-competitive purchase order. This medical device will be used to evaluate pulse wave velocity, central blood pressure, and coronary artery structure in research protocols focused on understanding vascular aging and atherosclerotic prevention in patients with diabetes and metabolic diseases. The procurement includes the SphygmoCor XCEL PWA/PWV system with multiple cuff sizes, a notebook computer, and a maintenance contract with specific support requirements. The system is noted as the only FDA-cleared device that combines central blood pressure and pulse wave velocity measurement in one platform. Interested parties may submit capability statements electronically by 5:00 PM EST on September 10, 2025, to jacob.balenson@nih.gov, and must maintain active System for Award Management (SAM) registration.

This procurement does not utilize any set-aside designations and is structured as a non-competitive award to the specified vendor, ATCOR MEDICAL INC USA. The total procurement value remains under the simplified acquisition threshold of $250,000, indicating a relatively modest contract size for the specialized medical equipment and associated services. Delivery requirements specify completion within 30 days after receipt of order, establishing a relatively tight timeline for fulfillment. The comprehensive nature of the procurement encompasses not only the primary medical device but also supporting equipment and ongoing maintenance services to ensure operational continuity for the research applications. The specific focus on diabetes and metabolic disease research underscores the specialized nature of this medical equipment procurement within the broader NIH research mission.